Acid-based parameters on ph-impedance testing predict symptom improvement with medical management better than impedance parameters

American Journal of Gastroenterology

Volumn 109, Issue 6, 2014, Pages 836-844

  Patel, Amit ^a   Sayuk, Gregory S ^a   Gyawali, C Prakash ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID EXPOSURE TIME; ADULT; ARTICLE; CHEMICAL PARAMETERS; COUGHING; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GHILLEBERT PROBABILITY ESTIMATE; HEARTBURN; HOARSENESS; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REFLUX EXPOSURE TIME; SYMPTOM INDEX; THORAX PAIN; THROAT CLEARING; THROAT DISEASE;

ADULT; AGED; ELECTRIC IMPEDANCE; ESOPHAGEAL PH MONITORING; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84902076762     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.63     Document Type: Article

References (45)

1. Shay S. Esophageal impedance monitoring: The ups and downs of a new test. Am J Gastroenterol 2004;99;1020-2. (Pubitemid 38917802
2. Prakash C, Jonnalagadda S. Esophageal impedance testing: Unraveling the mysteries of gastroesophageal refl ux. Gastroenterology 2006;131;322-3. (Pubitemid 44015766
3. Zerbib F, Roman S, des Verannes S, et al. Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clin Gastroenterol and Hepatol 2013;11;366-72
4. Bredenoord A, Wuesten B, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol 2006;101;453-9. (Pubitemid 43340918
5. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid refl ux in NERD: Lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008;103;2685-93
6. Karamanolis G, Kotsalidis G, Triantafyllou K, et al. Yield of combined impedance-pH monitoring for refractory refl ux symptoms in clinical practice. J Neurogastroenterol Motil 2011;17;158-63
7. Sifrim D, Castell D, Dent J, et al. Gastro-oesophageal refl ux monitoring: Review and consensus report on detection and defi nitions of acid, non-Acid, and gas refl ux. Gut 2004;53;1024-31. (Pubitemid 38824163
8. Hirano I, Richter J, the Practice Parameters Committee of the American College of Gastroenterology. ACG Practice Guidelines: Esophageal refl ux testing. Am J Gastroenterol 2007;102;668-85
9. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: A study in patients on and off therapy. Am J Gastroenterol 2006;101;1956-63. (Pubitemid 44337616
10. Mainie I, Tutuian R, Shay S, et al. Acid and non-Acid refl ux in patients with persistent symptoms despite acid suppressive therapy: A multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55;1398-402. (Pubitemid 44476780
11. Aanen M, Bredenoord A, Numans M, et al. Reproducibility of symptom association analysis in ambulatory refl ux monitoring. Am J Gastroenterol 2008;103;2200-8
12. Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008;6;521-4
13. Hemmink G, Bredenoord A, Wuesten B, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant refl ux symptoms: ' On ' or ' Off ' proton pump inhibitor. Am J Gastroenterol 2008;103;2446-53
14. Vaezi M. Refl ux monitoring: On or off therapy?. Am J Gastroenterol 2011;106;185
15. Pritchett J, Aslam M, Slaughter J, et al. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal refl ux disease, on and off therapy. Clin Gastroenterol Hepatol 2009;7;743-8
16. Roman S, Poncet G, Serraj I, et al. Characterization of refl ux events aft er fundoplication using combined impedance-pH recording. Br J Surg 2007;94;48-52. (Pubitemid 46142731
17. Patel A, Aadam A, Sayuk G, et al. Refl ux exposure time on ph-impedance testing predicts symptom improvement Aft er Antirefl ux Surgery (ARS) better than number of refl ux events. Gastroenterology 2012;142;S-423
18. Del Genio G, Tolone S, Del Genio F, et al. Prospective assessment of patient selection for antirefl ux surgery by combined multichannel intraluminal impedance pH monitoring. J Gastrointest Surg 2008;12;1491-6
19. Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastroesophageal refl ux for laparoscopic Nissen fundoplication. Br J Surg 2006;93;1483-7. (Pubitemid 44893649
20. Kushnir V, Gyawali CP. High resolution manometry patterns distinguish acid sensitivity in non-cardiac chest pain. Neurogastroenterol Motil 2011;23;1066-72
21. Stoikes N, Drapekin J, Kushnir V, et al. The value of multiple rapid swallows during preoperative esophageal manometry before laparoscopic antirefl ux surgery. Surg Endosc 2012;26;3401-7
22. Kahrilas PJ, Quigley EMM. Clinical esophageal pH recording: A technical review for practice guideline development. Gastroenterology 1996;110;1982-96
23. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: A multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004;99;1037-43. (Pubitemid 38917805
24. Ghillebert G, Janssens J, Vantrappen G, et al. Ambulatory 24-hour intraoesophageal pH and pressure recordings v provocation tests in the diagnosis of chest pain of oesophageal origin. Gut 1990;31;738-44. (Pubitemid 20233935
25. Weusten BLAM, Roelofs JMM, Akkermans LMA, et al. The symptom-Association probability: An improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994;107;1741-5. (Pubitemid 24357628
26. Weiner GJ, Richter JE, Copper JB, et al. The symptom index: A clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988;38;358-61
27. Pandolfi no J, Vela M. Technical review: Esophageal-refl ux monitoring. Gastrointest Endosc 2009;69;917-30
28. Avidan B, Sonnenberg A, Schnell T, et al. Hiatal hernia and acid refl ux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002;47;256-64. (Pubitemid 34123982
29. Vaezi M, Richter J. Role of acid and duodenogastroesophageal refl ux in gastroesophageal refl ux disease. Gastoenterology 1996;111;1192-9. (Pubitemid 26362243
30. Aanen M, Wuesten B, Numans M, et al. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-refl ux association. J Clin Gastroenterol 2008;42;441-7. (Pubitemid 351572258
31. Campos G, Peters J, DeMeester T, et al. Multivariate analysis of factors predicting outcome aft er laparoscopic Nissen fundoplication. J Gastrointest Surg 1999;3;292-300
32. Khajanchee Y, Hong D, Hansen P, et al. Outcomes of antirefl ux surgery in patients with normal preoperative 24-hour pH test results. Am J Surg 2004;187;599-603. (Pubitemid 38596878
33. Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pHimpedance, profi les predict response to proton pump inhibitors in gastrooesphageal refl ux disease. Gut 2012;61;501-6
34. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal refl ux disease. Gastroenterology 2008;135;1392-413
35. Sifrim D, Zerbib F. Diagnosis and management of patients with refl ux symptoms refractory to proton pump inhibitors. Gut 2012;61;1340-54
36. Kahrilas P. When proton pump inhibitors fail. Clin Gastroenterol Hepatol 2008;6;482-3
37. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on pH therapy. Am J Gastroenterol 2005;100;283-9. (Pubitemid 40314510
38. Slaughter J, Goutte M, Rymer J, et al. Caution about overinterpretation of symptom indexes in refl ux monitoring for refractory gastroesophageal refl ux disease. Clin Gastroenterol Hepatol 2011;9;868-74
39. Kushnir V, Sayuk G, Gyawali CP. The Effect of antisecretory therapy and study duration on ambulatory esophageal pH monitoring. Dig Dis Sci 2011;56;1412-9
40. Helm J, Dodds W, Pelc L, et al. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med 1984;310;284-8. (Pubitemid 14222041
41. Kahrilas P. Gastroesophageal refl ux disease. N Engl J Med 2008;359;1700-7
42. Katz P, Gerson L, Vela M. Guidelines for the diagnosis and management of gastroesophageal refl ux disease. Am J Gastroenterol 2013;108;308-28
43. Vela M, Tutuian R, Katz P, et al. Baclofen decreases acid and non-Acid postprandial gastro-oesophageal refl ux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003;17;243-51. (Pubitemid 36174255
44. Ciccaglione A, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 h pH metry and symptoms in control subjects and in patients with gastro-oesophageal refl ux disease. Gut 2003;4;464-70. (Pubitemid 36367205
45. Cossentino M, Mann K, Armbruster S, et al. Randomised clinical trial: The Effect of baclofen in patients with gastro-oesophageal refl ux-A randomised prospective study. Aliment Pharmacol Ther 2012;35;1036-44